Four Arms, Multicenter Study of Tailored Regimens With Peginterferon Plus Ribavirin for Genotype 2 Chronic Hepatitis C
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The purposes of this study are:
1. To evaluate the efficacy and safety of low-dose versus standard-dose of ribavirin in
combination with peginterferon alfa-2a given for 16 weeks in hepatitis C virus (HCV)
genotype 2 infected, treatment-naïve chronic hepatitis C patients after achieving a
rapid virologic response (RVR,defined as seronegativity of HCV RNA at week 4 of
treatment).
2. To evaluate the efficacy and safety of 24-week versus 48-week regimen of peginterferon
alfa-2a plus standard-dose of ribavirin in HCV genotype 2 infected, treatment-naïve
chronic hepatitis C patients who have no RVR.
Phase:
Phase 4
Details
Lead Sponsor:
Kaohsiung Medical University Chung-Ho Memorial Hospital